CSPC Pharmaceutical (HKG:1093) said a new drug application for Anbenitamab was accepted by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.
The application for Anbenitamab, co-developed by Shanghai JMT-Bio Technology, a unit of the company, and Alphamab Oncology (HKG:9966), has also been included in the priority review and approval procedures.
The indication for the application is Anbenitamab in combination with docetaxel (albumin-bound) ± carboplatin as neoadjuvant therapy to treat breast cancer in adults.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments